arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Evommune, Inc.

EVMN Health Care Biotechnology: Pharmaceutical Preparations
$5.10
▼ -1.4% Today
as of Oct 23, 16:48 ET
Last 30 days -51.10% Sep 14 → Oct 23
$4.67 $6.22 $7.77 $9.31 $10.86 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$5.18
High
$5.18
Low
$4.94
Volume
$280,527
Avg Vol
$589,584
Mkt Cap
$472M
P/E (TTM)
—
Beta
—
52w High
$33.20
52w Low
$4.94
Div Yield
—
Shares Out
$36M

Recent Press Releases & News last 60 days · 9 items

Oct 12 · 14:04 MT Newswires
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target
Oct 1 · 12:00 PR Business Wire
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Sep 23 · 20:05 PR Business Wire
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
▸ Show all 9 press releases & news Free account →

EVMN earnings at a glance

The options market is pricing a move of about ±28.7% after the report, a range of roughly $3.63 to $6.57 from today's $5.10. Over its last 1 reports the stock rose the next day 0 times and fell 1, moving ±5.6% on average; after the most recent report on May 7, 2026 it moved -5.6%. That means options currently expect more movement than EVMN has typically delivered. EVMN beat the consensus EPS estimate in 1 of its last 1 reported quarters. Implied volatility is currently 218%. The share price of $5.10 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$4.94
$33
1% of range
Avg surprise (last 1)
+22.9%
Avg reaction (last 1)
-5.6%
0% positive
Latest IV / EM
218%
EM ±28.7% · $8 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.47$-8.01$-5.56$-3.10$-0.64 Actual $-10.47Actual $-9.48Actual $-8.80Actual $-8.07Actual $-0.64Est $-0.83Actual $-0.89 SepMarJunSepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-22M$-11M$-186,500$10M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.89 — — — — financials
Thu May 7, 2026Mar/2026 $-0.64 $-0.83 +22.9% — -5.6% earnings
Tue Sep 30, 2025Sep 2025 $-8.07 — — — — financials
Mon Jun 30, 2025Jun 2025 $-8.80 — — — — financials
Mon Mar 31, 2025Mar 2025 $-9.48 — — — — financials
Mon Sep 30, 2024Sep 2024 $-10.47 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$10M$0$3M——
Cost of revenue————————
Gross profit————————
Operating income$-35M$-24M—$-13M$-23M$-15M—$-17M
Net income$-32M$-22M—$-12M$-14M$-15M—$-16M
EPS (diluted)$-0.89$-0.64—$-8.07$-8.80$-9.48—$-10.47

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$60M$48M$44M$27M$62M$6M$16M$18M
Inventory————————
Total current assets$204M$216M$153M$82M——$74M—
Total assets$302M$322M$225M$85M——$76M—
Long-term debt————————
Total liabilities$24M$18M$19M$11M——$29M—
Total equity$278M$305M$206M$-183M$-171M$-158M$-144M$-123M

Implied volatility — last 90 days

20%158%297%435%573% Jun 08 — IV 191% · EM ±25.3%Jun 17 — IV 574% · EM ±24.0%Jun 19 — IV 245% · EM ±54.1%Jun 22 — IV 267% · EM ±55.7%Jun 23 — IV 270% · EM ±55.3%Jun 24 — IV 257% · EM ±51.6%Jun 25 — IV 279% · EM ±54.7%Jun 26 — IV 267% · EM ±51.0%Jun 29 — IV 100% · EM ±17.7%Jun 30 — IV 123% · EM ±21.2%Jul 01 — IV 157% · EM ±26.2%Jul 02 — IV 149% · EM ±24.1%Jul 03 — IV 154% · EM ±24.1%Jul 06 — IV 196% · EM ±27.1%Jul 07 — IV 163% · EM ±21.6%Jul 08 — IV 39% · EM ±4.9%Jul 09 — IV 28% · EM ±3.3%Jul 10 — IV 20% · EM ±2.2%Jul 13 — IV 114% · EM ±9.5%Jul 14 — IV 144% · EM ±10.4%Jul 15 — IV 88% · EM ±5.2%Jul 16 — IV 368% · EM ±15.4%Jul 20 — IV 59% · EM ±13.9%Jul 21 — IV 192% · EM ±44.6%Jul 22 — IV 160% · EM ±36.6%Jul 23 — IV 153% · EM ±34.5%Jul 24 — IV 132% · EM ±29.1%Jul 27 — IV 167% · EM ±34.9%Jul 28 — IV 239% · EM ±48.9%Jul 29 — IV 226% · EM ±45.2%Jul 30 — IV 196% · EM ±38.3%Jul 31 — IV 232% · EM ±44.4%Aug 03 — IV 212% · EM ±37.5%Aug 04 — IV 137% · EM ±23.6%Aug 05 — IV 130% · EM ±21.7%Aug 06 — IV 127% · EM ±20.6%Aug 07 — IV 155% · EM ±24.1%Aug 10 — IV 267% · EM ±37.0%Aug 11 — IV 29% · EM ±3.8%Aug 13 — IV 60% · EM ±7.1%Aug 14 — IV 349% · EM ±38.6%Aug 19 — IV 79% · EM ±4.7%Aug 24 — IV 144% · EM ±30.0%Aug 25 — IV 170% · EM ±34.8%Aug 26 — IV 189% · EM ±37.9%Aug 27 — IV 177% · EM ±34.7%Aug 31 — IV 223% · EM ±39.5%Sep 01 — IV 109% · EM ±18.8%Sep 02 — IV 224% · EM ±37.5%Sep 03 — IV 258% · EM ±41.7%Sep 04 — IV 310% · EM ±48.5%Sep 07 — IV 350% · EM ±48.5%Sep 09 — IV 212% · EM ±26.5%Sep 10 — IV 405% · EM ±47.8%Sep 16 — IV 235% · EM ±13.9%Sep 21 — IV 129% · EM ±27.0%Sep 22 — IV 128% · EM ±26.2%Sep 23 — IV 139% · EM ±27.9%Sep 24 — IV 290% · EM ±56.8%Sep 30 — IV 156% · EM ±26.0%Oct 01 — IV 153% · EM ±24.7%Oct 02 — IV 162% · EM ±25.3%Oct 06 — IV 218% · EM ±28.7%

Sector peers

ARVN
Arvinas, Inc.
$487M $7.30-3.4%
DMAC
DiaMedica Therapeutics Inc.
$450M $8.72+0.3%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%
OCS
Oculis Holding AG
$508M $7.90+0.4%

EVMN earnings FAQ

What is EVMN's expected move for earnings?

Options currently price a move of about ±28.7%, or $1.47 per share either way from $5.10.

How does EVMN stock usually react to earnings?

Across the last 1 reports the average next-day move was ±5.6%, up 0 times and down 1 times.

What is EVMN's implied volatility?

EVMN's at-the-money implied volatility is about 218% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in